iRadimed Corp. (NASDAQ:IRMD) shares rose 5.7% during mid-day trading on Friday . The stock traded as high as $22.53 and last traded at $22.13, with a volume of 65,765 shares traded. The stock had previously closed at $20.93.

IRMD has been the topic of several research reports. Roth Capital reissued a “buy” rating on shares of iRadimed Corp. in a research report on Tuesday, May 3rd. Zacks Investment Research downgraded shares of iRadimed Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, March 16th.

The firm has a market cap of $241.57 million and a P/E ratio of 33.18. The stock has a 50-day moving average of $20.25 and a 200 day moving average of $19.12.

iRadimed Corp. (NASDAQ:IRMD) last announced its earnings results on Friday, April 29th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.03. The firm earned $8.96 million during the quarter, compared to analysts’ expectations of $9.05 million. iRadimed Corp.’s revenue for the quarter was up 28.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.17 earnings per share. On average, analysts anticipate that iRadimed Corp. will post $0.89 earnings per share for the current fiscal year.

In other news, Director Monty K. Allen sold 2,275 shares of the company’s stock in a transaction on Tuesday, June 14th. The shares were sold at an average price of $20.00, for a total value of $45,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Monty K. Allen sold 2,100 shares of the company’s stock in a transaction on Monday, June 13th. The shares were sold at an average price of $20.44, for a total transaction of $42,924.00. Following the completion of the transaction, the director now owns 4,375 shares of the company’s stock, valued at $89,425. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have recently made changes to their positions in IRMD. EAM Investors LLC increased its position in shares of iRadimed Corp. by 0.4% in the fourth quarter. EAM Investors LLC now owns 78,945 shares of the company’s stock valued at $2,213,000 after buying an additional 311 shares during the period. Russell Frank Co bought a new stake in iRadimed Corp. during the fourth quarter valued at about $2,675,000. GSA Capital Partners LLP boosted its stake in iRadimed Corp. by 174.3% in the fourth quarter. GSA Capital Partners LLP now owns 50,203 shares of the company’s stock valued at $1,407,000 after buying an additional 31,901 shares in the last quarter. Finally, AWM Investment Company Inc. boosted its stake in iRadimed Corp. by 79.2% in the fourth quarter. AWM Investment Company Inc. now owns 278,330 shares of the company’s stock valued at $7,802,000 after buying an additional 123,000 shares in the last quarter.

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.